133 related articles for article (PubMed ID: 19969452)
1. Sulfonylureido thiazoles as fructose-1,6-bisphosphatase inhibitors for the treatment of type-2 diabetes.
Kitas E; Mohr P; Kuhn B; Hebeisen P; Wessel HP; Haap W; Ruf A; Benz J; Joseph C; Huber W; Sanchez RA; Paehler A; Benardeau A; Gubler M; Schott B; Tozzo E
Bioorg Med Chem Lett; 2010 Jan; 20(2):594-9. PubMed ID: 19969452
[TBL] [Abstract][Full Text] [Related]
2. Orally active aminopyridines as inhibitors of tetrameric fructose-1,6-bisphosphatase.
Hebeisen P; Haap W; Kuhn B; Mohr P; Wessel HP; Zutter U; Kirchner S; Ruf A; Benz J; Joseph C; Alvarez-Sánchez R; Gubler M; Schott B; Benardeau A; Tozzo E; Kitas E
Bioorg Med Chem Lett; 2011 Jun; 21(11):3237-42. PubMed ID: 21550236
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase.
Dang Q; Liu Y; Cashion DK; Kasibhatla SR; Jiang T; Taplin F; Jacintho JD; Li H; Sun Z; Fan Y; DaRe J; Tian F; Li W; Gibson T; Lemus R; van Poelje PD; Potter SC; Erion MD
J Med Chem; 2011 Jan; 54(1):153-65. PubMed ID: 21126019
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes.
Dang Q; Kasibhatla SR; Reddy KR; Jiang T; Reddy MR; Potter SC; Fujitaki JM; van Poelje PD; Huang J; Lipscomb WN; Erion MD
J Am Chem Soc; 2007 Dec; 129(50):15491-502. PubMed ID: 18041834
[TBL] [Abstract][Full Text] [Related]
5. Managlinat dialanetil, a fructose-1,6-bisphosphatase inhibitor for the treatment of type 2 diabetes.
Wang Y; Tomlinson B
Curr Opin Investig Drugs; 2007 Oct; 8(10):849-58. PubMed ID: 17907062
[TBL] [Abstract][Full Text] [Related]
6. 2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice.
Johansson L; Fotsch C; Bartberger MD; Castro VM; Chen M; Emery M; Gustafsson S; Hale C; Hickman D; Homan E; Jordan SR; Komorowski R; Li A; McRae K; Moniz G; Matsumoto G; Orihuela C; Palm G; Veniant M; Wang M; Williams M; Zhang J
J Med Chem; 2008 May; 51(10):2933-43. PubMed ID: 18419108
[TBL] [Abstract][Full Text] [Related]
7. Structure-based drug design of tricyclic 8H-indeno[1,2-d][1,3]thiazoles as potent FBPase inhibitors.
Tsukada T; Takahashi M; Takemoto T; Kanno O; Yamane T; Kawamura S; Nishi T
Bioorg Med Chem Lett; 2010 Feb; 20(3):1004-7. PubMed ID: 20045638
[TBL] [Abstract][Full Text] [Related]
8. Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy.
Thomson SA; Banker P; Bickett DM; Boucheron JA; Carter HL; Clancy DC; Cooper JP; Dickerson SH; Garrido DM; Nolte RT; Peat AJ; Sheckler LR; Sparks SM; Tavares FX; Wang L; Wang TY; Weiel JE
Bioorg Med Chem Lett; 2009 Feb; 19(4):1177-82. PubMed ID: 19138846
[TBL] [Abstract][Full Text] [Related]
9. Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
Vu CB; Bemis JE; Disch JS; Ng PY; Nunes JJ; Milne JC; Carney DP; Lynch AV; Smith JJ; Lavu S; Lambert PD; Gagne DJ; Jirousek MR; Schenk S; Olefsky JM; Perni RB
J Med Chem; 2009 Mar; 52(5):1275-83. PubMed ID: 19199480
[TBL] [Abstract][Full Text] [Related]
10. Substituted tetrahydropyrrolo[2,1-b]oxazol-5(6H)-ones and tetrahydropyrrolo[2,1-b]thiazol-5(6H)-ones as hypoglycemic agents.
Aicher TD; Balkan B; Bell PA; Brand LJ; Cheon SH; Deems RO; Fell JB; Fillers WS; Fraser JD; Gao J; Knorr DC; Kahle GG; Leone CL; Nadelson J; Simpson R; Smith HC
J Med Chem; 1998 Nov; 41(23):4556-66. PubMed ID: 9804695
[TBL] [Abstract][Full Text] [Related]
11. Structure-guided design of AMP mimics that inhibit fructose-1,6-bisphosphatase with high affinity and specificity.
Erion MD; Dang Q; Reddy MR; Kasibhatla SR; Huang J; Lipscomb WN; van Poelje PD
J Am Chem Soc; 2007 Dec; 129(50):15480-90. PubMed ID: 18041833
[TBL] [Abstract][Full Text] [Related]
12. Fructose-1,6-bisphosphatase Inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 5'-adenosinemonophosphate (AMP) mimics.
Dang Q; Kasibhatla SR; Xiao W; Liu Y; Dare J; Taplin F; Reddy KR; Scarlato GR; Gibson T; van Poelje PD; Potter SC; Erion MD
J Med Chem; 2010 Jan; 53(1):441-51. PubMed ID: 20055427
[TBL] [Abstract][Full Text] [Related]
13. Novel euglycemic and hypolipidemic agents. 4. Pyridyl- and quinolinyl-containing thiazolidinediones.
Lohray BB; Bhushan V; Reddy AS; Rao PB; Reddy NJ; Harikishore P; Haritha N; Vikramadityan RK; Chakrabarti R; Rajagopalan R; Katneni K
J Med Chem; 1999 Jul; 42(14):2569-81. PubMed ID: 10411477
[TBL] [Abstract][Full Text] [Related]
14. Allosteric FBPase inhibitors gain 10(5) times in potency when simultaneously binding two neighboring AMP sites.
Hebeisen P; Kuhn B; Kohler P; Gubler M; Huber W; Kitas E; Schott B; Benz J; Joseph C; Ruf A
Bioorg Med Chem Lett; 2008 Aug; 18(16):4708-12. PubMed ID: 18650089
[TBL] [Abstract][Full Text] [Related]
15. Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones.
Reddy KA; Lohray BB; Bhushan V; Bajji AC; Reddy KV; Reddy PR; Krishna TH; Rao IN; Jajoo HK; Rao NV; Chakrabarti R; Dileepkumar T; Rajagopalan R
J Med Chem; 1999 Jun; 42(11):1927-40. PubMed ID: 10354401
[TBL] [Abstract][Full Text] [Related]
16. SAR and optimization of thiazole analogs as potent stearoyl-CoA desaturase inhibitors.
Ramtohul YK; Black C; Chan CC; Crane S; Guay J; Guiral S; Huang Z; Oballa R; Xu LJ; Zhang L; Li CS
Bioorg Med Chem Lett; 2010 Mar; 20(5):1593-7. PubMed ID: 20137926
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of novel imidazoline derivatives with potent antihyperglycemic activity in a rat model of type 2 diabetes.
Crane L; Anastassiadou M; El Hage S; Stigliani JL; Baziard-Mouysset G; Payard M; Leger JM; Bizot-Espiard JG; Ktorza A; Caignard DH; Renard P
Bioorg Med Chem; 2006 Nov; 14(22):7419-33. PubMed ID: 16889967
[TBL] [Abstract][Full Text] [Related]
18. Structure-based design of potent retinoid X receptor alpha agonists.
Haffner CD; Lenhard JM; Miller AB; McDougald DL; Dwornik K; Ittoop OR; Gampe RT; Xu HE; Blanchard S; Montana VG; Consler TG; Bledsoe RK; Ayscue A; Croom D
J Med Chem; 2004 Apr; 47(8):2010-29. PubMed ID: 15056000
[TBL] [Abstract][Full Text] [Related]
19. Novel euglycemic and hypolipidemic agents. 1.
Lohray BB; Bhushan V; Rao BP; Madhavan GR; Murali N; Rao KN; Reddy AK; Rajesh BM; Reddy PG; Chakrabarti R; Vikramadithyan RK; Rajagopalan R; Mamidi RN; Jajoo HK; Subramaniam S
J Med Chem; 1998 May; 41(10):1619-30. PubMed ID: 9572887
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, SAR, and X-ray structure of tricyclic compounds as potent FBPase inhibitors.
Tsukada T; Takahashi M; Takemoto T; Kanno O; Yamane T; Kawamura S; Nishi T
Bioorg Med Chem Lett; 2009 Oct; 19(20):5909-12. PubMed ID: 19762234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
